Ibuprofen
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Ibuprofen
- Generic name
- IBUPROFEN
- Manufacturer
- Advanced Rx of Tennessee, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 19b06eaf-0d4c-2b4d-e063-6294a90a2eb9
- SPL ID
- 1f0759c8-a2f7-a26c-e063-6294a90aa78a
- Version
- 2
- Effective date
- 2024-08-06
- Source export date
- 2026-11-13
- Source partition
- 7
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0007-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/875ce92e4370b2000cf566c8a9c0e4d02cceccd3a3b18a8b0b87928b28506f0b/drug-label-0007-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:31:29
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 090796 | derived:openfda.application_number |
| application number | ANDA090796 | openfda.application_number | |
| brand name | Ibuprofen | openfda.brand_name | |
| generic name | IBUPROFEN | openfda.generic_name | |
| manufacturer name | Advanced Rx of Tennessee, LLC | openfda.manufacturer_name | |
| ndc | package | 80425-0426-4 | openfda.package_ndc |
| ndc | package | 80425-0393-2 | openfda.package_ndc |
| ndc | package | 80425-0393-4 | openfda.package_ndc |
| ndc | package | 80425-0393-5 | openfda.package_ndc |
| ndc | package | 80425-0426-3 | openfda.package_ndc |
| ndc | package | 80425-0426-2 | openfda.package_ndc |
| ndc | package | 80425-0393-1 | openfda.package_ndc |
| ndc | package | 80425-0426-1 | openfda.package_ndc |
| ndc | package | 80425-0393-3 | openfda.package_ndc |
| ndc | product | 80425-0426 | openfda.product_ndc |
| ndc | product | 80425-0393 | openfda.product_ndc |
| ndc11 | package | 80425042603 | derived:openfda.package_ndc |
| ndc11 | package | 80425042602 | derived:openfda.package_ndc |
| ndc11 | package | 80425039303 | derived:openfda.package_ndc |
| ndc11 | package | 80425039302 | derived:openfda.package_ndc |
| ndc11 | package | 80425042604 | derived:openfda.package_ndc |
| ndc11 | package | 80425039301 | derived:openfda.package_ndc |
| ndc11 | package | 80425039304 | derived:openfda.package_ndc |
| ndc11 | package | 80425042601 | derived:openfda.package_ndc |
| ndc11 | package | 80425039305 | derived:openfda.package_ndc |
| rxcui | 197807 | openfda.rxcui | |
| rxcui | 197806 | openfda.rxcui | |
| spl id | 1f0759c8-a2f7-a26c-e063-6294a90aa78a | id | |
| spl set id | 19b06eaf-0d4c-2b4d-e063-6294a90a2eb9 | set_id | |
| unii | WK2XYI10QM | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
Cardiovascular Thrombotic Events · Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (see WARNINGS and PRECAUTIONS ) . · Ibuprofen Tablets is contraindicated in the setting of coronary artery bypass graft (CABG) surgery (see CONTRAINDICATIONS and WARNINGS ) . Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. (see WARNINGS ).
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
Advanced Renal Disease No information is available from controlled clinical studies regarding the use of ibuprofen tablets in patients with advanced renal disease. Therefore, treatment with ibuprofen tablets is not recommended in these patients with advanced renal disease. If ibuprofen tablet therapy must be initiated, close monitoring of the patients renal function is advisable.
warnings
Anaphylactoid Reactions As with other NSAIDs, anaphylactoid reactions may occur in patients without known prior exposure to ibuprofen tablets. Ibuprofen tablets should not be given to patients with the aspirin triad. This symptom complex typically occurs in asthmatic patients who experience rhinitis with or without nasal polyps, or who exhibit severe, potentially fatal bronchospasm after taking aspirin or other NSAIDs (see CONTRAINDICATIONS and PRECAUTIONS, Preexisting Asthma ). Emergency help should be sought in cases where an anaphylactoid reaction occurs.
warnings
Skin Reactions NSAIDs, including ibuprofen tablets, can cause serious skin adverse events such as exfoliative dermatitis, Stevens - Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. These serious events may occur without warning. Patients should be informed about the signs and symptoms of serious skin manifestations and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as ibuprofen tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue ibuprofen tablets and evaluate the patient immediately.
warnings
Fetal Toxicity Premature Closure of Fetal Ductus Arteriosus: Avoid use of NSAIDs, including ibuprofen tablets, in pregnant women at about 30 weeks gestation and later. NSAIDs including ibuprofen tablets, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age. Oligohydramnios/Neonatal Renal Impairment: Use of NSAIDs, including ibuprofen tablets, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required. If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ibuprofen tablets use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if ibuprofen tablets treatment extends beyond 48 hours. Discontinue ibuprofen tablets if oligohydramnios occurs and follow up according to clinical practice [see PRECAUTIONS; Pregnancy ].
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS The most frequent type of adverse reaction occurring with ibuprofen tablets is gastrointestinal. In controlled clinical trials the percentage of patients reporting one or more gastrointestinal complaints ranged from 4% to 16%. In controlled studies when ibuprofen tablets were compared to aspirin and indomethacin in equally effective doses, the overall incidence of gastrointestinal complaints was about half that seen in either the aspirin or indomethacin treated patients. Adverse reactions observed during controlled clinical trials at an incidence greater than 1% are listed in the table. Those reactions listed in Column one encompass observations in approximately 3,000 patients. More than 500 of these patients were treated for periods of at least 54 weeks. Still other reactions occurring less frequently than 1 in 100 were reported in controlled clinical trials and from marketing experience. These reactions have been divided into two categories: Column two of the table lists reactions with therapy with ibuprofen tablets where the probability of a causal relationship exists: for the reactions in Column three, a causal relationship with ibuprofen tablets has not been established. Reported side effects were higher at doses of 3200 mg/day than at doses of 2400 mg or less per day in clinical trials of patients with rheumatoid arthritis. The increases in incidence were slight and still within the ranges reported in the table. Incidence Greater than 1% (but less than 3%) Probable Causal Relationship Precise Incidence Unknown (but less than 1%) Probable Causal Relationship** Precise Incidence Unknown (but less than 1%) Causal Relationship Unknown** GASTROINTESTINAL Nausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of GI tract (bloating and flatulence) Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; pancreatitis Depression, insomnia, confusion, emotional liability, somnolence, aseptic, meningitis with fever and coma (see PRECAUTIONS ) CENTRAL NERVOUS SYSTEM Dizziness*, headache, nervousness. Depression, insomnia, confusion, emotional liability, somnolence, aseptic, meningitis with fever and coma (see PRECAUTIONS ) Paresthesias, hallucinations, dream abnormalities, pseudo-tumorcerebri DERMATOLOGIC Rash*, (including maculopapular type), pruritus. Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia Toxic epidermal necrolysis, photoallergic skin reactions HEMATOLOGIC Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit (see PRECAUTIONS ) Bleeding episodes (e.g., epistaxis, menorrhagia) METABOLIC/ENDOCRINE Decreased appetite Gynecomastia, hypoglycemic reaction, acidosis CARDIOVASCULAR Edema, fluid retention (generally responds promptly to drug discontinuation) (see PRECAUTIONS) Congestive heart failure in patients with marginal cardiac function, elevate blood pressure, palpitations Arrhythmias (sinus tachycardia, sinus bradycardia) ALLERGIC Syndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm (see CONTRAINDICATIONS) Serum sickness, lupus erythematosus syndrome. HenochSchonlein vasculitis, angioedema RENAL Acute renal failure (see PRECAUTIONS), decreased creatinine clearance, poliuria, azotemia, cystitis, Hematuria Renal papillary necrosis MISCELLANEOUS Dry eyes and mouth, gingival ulcer, rhinitis *Reactions occurring in 3% to 9% of patients treated with ibuprofen. (Those reactions occurring in less than 3% of the patients are unmarked). **Reactions are classified under “ Probable Causal Relationship (PCR) ” if there has been one positive rechallenge or if three or more cases occur which might be causally related. Reactions are classified under “Causal Relationship Unknown” if seven or more events have been reported but the criteria for PCR have not been met.
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="643"><col width="33.3333333333333%"/><col width="33.3333333333333%"/><col width="33.3333333333333%"/><thead><tr><th align="center" styleCode="Lrule Rrule Toprule"> <content styleCode="bold"> </content><content styleCode="bold"> Incidence Greater than 1%</content><content styleCode="bold">(but less than 3%)</content> <content styleCode="bold">Probable Causal Relationship</content> <content styleCode="bold"> </content></th><th styleCode="Lrule Rrule Toprule"><content styleCode="bold"> </content> <content styleCode="bold">Precise Incidence Unknown</content> <content styleCode="bold">(but less than 1%)</content> <content styleCode="bold">Probable Causal Relationship**</content> </th><th styleCode="Lrule Rrule Toprule"><content styleCode="bold"> </content><content styleCode="bold">Precise Incidence Unknown</content> <content styleCode="bold">(but less than 1%)</content> <content styleCode="bold">Causal Relationship Unknown**</content> </th></tr></thead><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">GASTROINTESTINAL </content> Nausea*, epigastric pain*, heartburn*, diarrhea, abdominal distress, nausea and vomiting, indigestion, constipation, abdominal cramps or pain, fullness of GI tract (bloating and flatulence) </td><td styleCode="Rrule" valign="top">Gastric or duodenal ulcer with bleeding and/or perforation, gastrointestinal hemorrhage, melena, gastritis, hepatitis, jaundice, abnormal liver function tests; pancreatitis </td><td styleCode="Rrule" valign="top">Depression, insomnia, confusion, emotional liability, somnolence, aseptic, meningitis with fever and coma (see <content styleCode="bold">PRECAUTIONS</content>) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">CENTRAL NERVOUS SYSTEM</content> Dizziness*, headache, nervousness. </td><td styleCode="Rrule" valign="top">Depression, insomnia, confusion, emotional liability, somnolence, aseptic, meningitis with fever and coma (see <content styleCode="bold">PRECAUTIONS</content>) </td><td styleCode="Rrule" valign="top">Paresthesias, hallucinations, dream abnormalities, pseudo-tumorcerebri </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">DERMATOLOGIC</content> Rash*, (including maculopapular type), pruritus. </td><td styleCode="Rrule" valign="top">Vesiculobullous eruptions, urticaria, erythema multiforme, Stevens-Johnson syndrome, alopecia </td><td styleCode="Rrule" valign="top">Toxic epidermal necrolysis, photoallergic skin reactions </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">HEMATOLOGIC</content> </td><td styleCode="Rrule" valign="top">Neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia (sometimes Coombs positive), thrombocytopenia with or without purpura, eosinophilia, decreases in hemoglobin and hematocrit (see <content styleCode="bold">PRECAUTIONS</content>) </td><td styleCode="Rrule" valign="top">Bleeding episodes (e.g., epistaxis, menorrhagia) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">METABOLIC/ENDOCRINE</content> Decreased appetite </td><td styleCode="Rrule" valign="top"> </td><td styleCode="Rrule" valign="top">Gynecomastia, hypoglycemic reaction, acidosis </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">CARDIOVASCULAR</content> Edema, fluid retention (generally responds promptly to drug discontinuation) (see PRECAUTIONS) </td><td styleCode="Rrule" valign="top">Congestive heart failure in patients with marginal cardiac function, elevate blood pressure, palpitations </td><td styleCode="Rrule" valign="top">Arrhythmias (sinus tachycardia, sinus bradycardia) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">ALLERGIC</content> </td><td styleCode="Rrule" valign="top">Syndrome of abdominal pain, fever, chills, nausea and vomiting; anaphylaxis; bronchospasm (see CONTRAINDICATIONS) </td><td styleCode="Rrule" valign="top">Serum sickness, lupus erythematosus syndrome. HenochSchonlein vasculitis, angioedema </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">RENAL</content> </td><td styleCode="Rrule" valign="top">Acute renal failure (see PRECAUTIONS), decreased creatinine clearance, poliuria, azotemia, cystitis, Hematuria </td><td styleCode="Rrule" valign="top">Renal papillary necrosis </td></tr><tr><td styleCode="Lrule Rrule" valign="top"><content styleCode="bold">MISCELLANEOUS</content> </td><td styleCode="Rrule" valign="top">Dry eyes and mouth, gingival ulcer, rhinitis </td><td styleCode="Rrule" valign="top"> </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.